阿来替尼治疗ALK阳性非小细胞肺癌:1例报告及文献复习

Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:A Case Report and Literature Review

肺癌是我国乃至全球发病率及死亡率均较高的恶性肿瘤,其中非小细胞肺癌占80%左右,间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)基因突变的患者约占5%。ALK抑制剂阿来替尼的疗效优异,药物治疗不良反应的及时发现、及早治疗能极大地提高患者的临床获益。现报道包头市中心医院2020年4月收治的1例ALK阳性非小细胞肺癌的诊断、治疗及药物副反应处理,并文献复习。

Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world,of which non-small cell lung cancer accounts for about 80%.Anaplastic lymphoma kinase(ALK)gene mutation accounts for about 5%.Alectinib,ALK-tyrosine kinase inhibitor(ALK-TKI),has great performance in clinical.The early detection and treatment of adverse drug reactions can greatly improve clinical benefits.This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020.The diagnosis and treatment was retrospectively analyzed,and the literature was reviewed.